Skip to main content
. 2021 Jun 14;54(7):e13081. doi: 10.1111/cpr.13081

FIGURE 9.

FIGURE 9

YTH‐60 exerts therapeutic role in the period of BLM‐induced pulmonary fibrosis during the fibrogenic phase. Mice were administered with BLM (2 mg·kg−1) and then treated once a day by YTH‐60 or Nintedanib (30 mg·kg−1) from day 7 to day 14 after BLM challenge. A, Lung tissues stained with H&E or Masson staining. B, The experimental schedule. C, Ashcroft scoring. D, Hydroxyproline content of lung tissues. n = 3‐8 for each group, *P < .05; ***P < .001, Data are presented as mean ± SD